Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19

NCT04540185 is registered in ClinicalTrials.gov with Biomed Industries, Inc. as lead sponsor.

NCT NCT04540185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04540185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19
Lead sponsor
Biomed Industries, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
November 1, 2020
Completion date
December 31, 2022
Enrollment
3,600 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars (severe acute respiratory syndrome), sars-cov infection, sars-cov-2